Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

ANTA PHAR
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 -
EBIT 2018 -37,2 M
Net income 2018 -31,1 M
Debt 2018 -
Yield 2018 -
Sales 2019 9,34 M
EBIT 2019 -33,1 M
Net income 2019 -32,9 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0,83x
Capitalization 7,75 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases.It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A... 
More about the company
Latest news on ANTA PHAR
04/17ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Costs Associated with ..
AQ
04/16ANTHERA PHARMACEUTICALS INC : Costs Associated with Exit or Disposal Activities,..
AQ
03/18ANTHERA PHARMACEUTICALS : Ends Development of Treatment for Cystic Fibrosis-rela..
AQ
03/16ANTHERA PHARMACEUTICALS : Reports Top Line Data from the RESULT Phase 3 Clinical..
AQ
03/14ANTHERA PHARMACEUTICALS : pulls the plug on Sollpura after Phase 3 failure, shar..
AQ
03/13HERE’S WHAT’S MOVING ANT : ANTH) and Advaxis, Inc. (NASDAQ:ADXS)
AQ
03/13ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Financial Statements a..
AQ
03/13ANTHERA PHARMACEUTICALS : Reports Top Line Data from the RESULT Phase 3 Clinical..
AQ
03/12ANTHERA PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (f..
AQ
03/12ANTHERA PHARMACEUTICALS : Reports Top Line Data from the RESULT Phase 3 Clinical..
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Chart ANTA PHAR
Duration : Period :
ANTA PHAR Technical Analysis Chart | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 6,50 $
Spread / Average Target 1 806%
EPS Revisions
Managers
NameTitle
John Craig Thompson President, CEO & Executive Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
William R. Shanahan Chief Medical Officer
David E. Thompson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR8
GILEAD SCIENCES5.64%98 675
VERTEX PHARMACEUTICALS9.01%41 476
REGENERON PHARMACEUTICALS-14.19%34 613
GENMAB24.15%12 833
BEIGENE LTD (ADR)75.73%9 059